Investigational drug · Phase 3
CM326
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Moderate to Severe Asthma.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
13
Any phase or sponsor naming "CM326"
First trial start
2025
Dec 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CM326", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease
- Chronic Rhinosinusitis With Nasal Polyps
- Moderate to Severe Asthma
Approved drugs for the same conditions: Asthma · COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "CM326" as an intervention, largest first.
- A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07418736 · 318 participants (planned) · Start Dec 18, 2025 · Primary completion Jul 1, 2027
Drug: CM326 dose 1; CM326 dose 2 · For: Chronic Obstructive Pulmonary Disease
Sites: Beijing, China
- The Study of CM326 in Moderate-to-severe Atopic DermatitisPivotal-lookingStatus unknown
Keymed Biosciences Co.LtdIndustry
NCT05671432 · 240 participants (planned) · Start Dec 27, 2022 · Primary completion Dec 30, 2023
Drug: CM326 · For: Moderate-to-severe Atopic Dermatitis
Sites: Beijing, China
- A Phase III Study of CM326 in Subjects With Moderate to Severe AsthmaPivotal-lookingRecruiting
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT07372287 · 230 participants (planned) · Start Jan 23, 2026 · Primary completion Dec 31, 2028
Drug: CM326 · For: Moderate to Severe Asthma
Sites: Shanghai, China
- A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal PolyposisPivotal-lookingNot yet recruiting
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT07420257 · 212 participants (planned) · Start Feb 28, 2026 · Primary completion Oct 30, 2028
Drug: CM326 injection; Placebo of CM326 · For: Chronic Rhinosinusitis With Nasal Polyps
- A Study of CM326 in Subjects With Moderate to Severe AsthmaPivotal-lookingStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05774340 · 207 participants (planned) · Start May 18, 2023 · Primary completion Jan 2025
Drug: CM326 · For: Moderate to Severe Asthma
Sites: Shanghai, China
- A Comparative Pharmacokinetic Study of CM326 in Healthy SubjectsPivotal-lookingNot yet recruiting
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
NCT07560033 · 192 participants (planned) · Start Apr 20, 2026 · Primary completion Oct 1, 2026
Drug: CM326(formulation 1); CM326(formulation 2) · For: Healthy Subjects
Keymed Biosciences Co.LtdIndustry
NCT05671445 · 100 participants (planned) · Start Feb 9, 2023 · Primary completion Mar 28, 2024
Drug: CM326 · For: Atopic Dermatitis
Sites: Beijing, China
Keymed Biosciences Co.LtdIndustry
NCT06372678 · 90 participants (planned) · Start Jun 30, 2024 · Primary completion Jun 30, 2026
Drug: CM326; Placebo · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: Beijing, China
Keymed Biosciences Co.LtdIndustry
NCT05324137 · 88 participants · Start Jul 11, 2022 · Primary completion Mar 29, 2024
Drug: CM326 · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: Beijing, China
Keymed Biosciences Co.LtdIndustry
NCT05186922 · 54 participants (planned) · Start Feb 17, 2022 · Primary completion Jan 2023
Drug: CM326 · For: Moderate-to-severe Atopic Dermatitis
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial.
Xian M, Lan F, Yan B, et al. · Nat Commun 2025
- Translational Investigation of CM326 from Preclinical Studies to Randomized Phase I Clinical Trials in Healthy Adults.
Di Y, Yang L, Zhou J, et al. · BioDrugs 2025
- Anti-thymic stromal lymphopoietin monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps (DUBHE): Rationale and design of a multicenter, randomized, double-blind, placebo-controlled study.
Shen S, Xian M, Yan B, et al. · Asia Pac Allergy 2024
- Changes of Volume Parameters in the Treatment of Graves Ophthalmopathy by Endoscopic Transethmoidal Decompression of the Orbital Inner Wall Combined with Fat Decompression.
Fu W · Scanning 2022
Also in development for Chronic Obstructive Pulmonary Disease
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- AstegolimabPhase 33 trials
Roche (Genentech) · Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)
- TQC3721 forPhase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Obstructive Pulmonary Disease, Pulmonary Disease, Chronic Obstructive
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.